Clinical trial NCT06911632: Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Official title: MOMENTOUS Study (iMpact Of an Ecg ai ModEl oN The Diagnosis Of pUlmonary hypertenSion)
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Pulmonary Hypertension
Interstitial Lung Disease (ILD)
Keywords: Pulmonary Hypertension
Interstitial lung disease (ILD)
Lead sponsor: Tempus AI
Sponsor class: INDUSTRY
Collaborators: name: United Therapeutics
First posted: 2025-04-04
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: An ECG-based AI device, will provide a prediction of a participant's risk of having undiagnosed pulmonary hypertension. Participants with a high risk prediction in the Device group will undergo a transthoracic echocardiogram and a right heart catheterization (RHC). All other participants will receive standard of care treatment.
Primary purpose: DIAGNOSTIC

Brief summary: MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.

Detailed description: The goal of this study is to evaluate the use of an ECG-based AI device that may help predict if participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension (PH). The study seeks to determine whether use of the device increases the rate of new PH diagnoses over a period of 6 months as compared to current standard of care.

The study will recruit participants with ILD from lung disease clinics who will each receive a 12-lead ECG (a test that measures the electrical activity of the heart) following consent. The device will analyze the 12-lead ECG results to identify participants that are at high risk of having undiagnosed PH.

Participants will be randomly assigned to either the Device or Control group. For participants in the Device group investigators will receive the results of the device. In the Control group investigators will not receive the results of the device. Additionally, participants in the Device group identified as "high risk" by the device will receive a transthoracic echocardiogram and a right heart catheterization (RHC). Participants in the Device group who are not high risk and all participants in the Control group will not receive these additional tests as part of the study, but will receive standard of care treatment as determined by their physicians, which may include an echocardiogram or RHC if clinically indicated.

Eligibility criteria: Inclusion Criteria:

* 18 years or older at the time of consent
* A known diagnosis of interstitial lung disease
* Willing and able to provide informed consent and undergo all study-specific procedures, including echo and RHC, if required

Exclusion Criteria:

* A known diagnosis of pulmonary hypertension (including patients prescribed a therapy specifically for pulmonary arterial hypertension (PAH))
* A RHC was completed within the previous 1 year or ordered and not yet completed at the time of consent
* LV ejection fraction ≤ 40% on most recent echo or cardiac MRI, if available
* Unclassifiable Tempus PH ECG risk result after up to 2 ECG acquisitions
* A contraindication to RHC exists (for example, mechanical right heart valve)
* Physician decision that if a patient is directed to RHC by the study protocol, the potential risks of RHC outweigh the potential benefits
* There is a severe concomitant illness limiting life expectancy to less than 6 months (at the discretion of the investigator)
* There is a medical or social factor that makes the patient a poor candidate for the study and/or unlikely to be able to comply with the study protocol or complete study procedures (at the discretion of the investigator)

Primary outcomes:
measure: Proportion of participants receiving a new diagnosis of PH within the High risk Device group compared to the High risk Control group.
timeFrame: Through study completion, approximately 6 months
Secondary outcomes:
measure: Proportion of participants receiving a new diagnosis of PH within the Device group compared to the Control group.
timeFrame: Through study completion, approximately 6 months
measure: Proportion of participants receiving a new diagnosis of PH within the High risk Device group compared to the Not high risk Device group.
timeFrame: Through study completion, approximately 6 months
Other outcomes:
Locations:
Study officials:
References: